Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Consulting agrmnt
Director departure
Appointed COO
Appointed director
Organicell Regenerative Medicine, Inc. (BPSR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Completion of Acquisition or Disposition of Assets  Interactive Data
07/26/2023 8-K Quarterly results
07/11/2023 8-K Quarterly results
06/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Organicell Welcomes Howard Golub, MD, PhD as its New EVP/CSO Fort Lauderdale, FL / June 29, 2023 / Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Howard L. Golub, MD, PhD as its new Executive Vice President and Chief Science Officer . Dr. Golub has a distinguished background as a highly innovative healthcare executive and entrepreneur with extensive experience serving in C-suite roles – in both early-stage and large companies. Dr. Golub's exceptional career spans over 30 years of success advancing breakthroughs in the development of clinical therapeutics. Dr. Golub is the founder and a principal at Care-Safe LLC - a clinical research ..."
06/09/2023 8-K Other Events  Interactive Data
06/06/2023 8-K Investor presentation
Docs: "Employment Agreement with Dr. Harry Leider",
"Employment Agreement with Dr. Howard L. Golub",
"of the Private Securities Litigation Reform Act of 1995"
05/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/21/2023 8-K Quarterly results
03/08/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT , dated as of March 6, 2023, by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation, with headquarters located at 3321 College Avenue, Suite 246, Davie, FL 33314 , and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan Street, Suite J, Hollywood, FL 33021 . WHEREAS: A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission under the Securities Act of 1933, as amended ; B. The Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions s...",
"Promissory Note made in favor of AJB Capital Investments",
"Warrant issued to AJB Capital Investments"
12/23/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/25/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
10/12/2022 8-K/A Investor presentation
10/12/2022 8-K Investor presentation
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Schedule ‘A’"
09/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXHIBT 99.1"
09/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
09/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/09/2022 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
09/06/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PURCHASE AGREEMENT THIS PURCHASE AGREEMENT , dated as of September 1, 2022, is entered into by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation , and TYSADCO PARTNERS, LLC, a Delaware limited liability company . WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to purchase from the Company, up to Ten Million Dollars of the Company’ s common stock, par value $0.001 per share . The shares of Common Stock to be purchased hereunder are referred to herein as the “ Purchase Shares .” NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Compan...",
"TO REGISTRATION RIGHTS AGREEMENT"
08/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/23/2022 8-K Quarterly results
07/26/2022 8-K Appointed COO
Docs: "Press Release"
07/20/2022 8-K Quarterly results
07/19/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
01/13/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications and other clinical trial related activities surrounding Zofin TM , its principal product. Zofin™ , is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues."
11/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ORGANICELL REGNERATIVE MEDICINE, INC. UPLIST OF COMMON STOCK TO OTCQB APPROVED Common Stock to trade on OTCQB under the symbol “OCEL” commencing November 9, 2021 PRESS RELEASE Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market has been approved by OTC Markets Group, Inc. Organicell’ s common stock will commence trading on the OTCQB under the symbol “OCEL” commencing at the opening of the market on November 9, 2021. The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. To be listed on OTCQB, companies must be current in..."
11/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Miami, FL — Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial Industry Regulatory Agency that the pending marketplace name change and trading symbol change request to Organicell Regenerative Medicine, Inc. and “OCEL” has been approved. Accordingly, effective Monday November 8, 2021, the company will have the marketplace name Organicell Regenerative Medicine, Inc. and Organicell common stock will begin trading under the symbol “OCEL” on the OTCPink tier of the over-the -counter market operated by OTC Markets Group, Inc. · New Marketplace Name: Organicell Regenerative Medicine, Inc. · New Symbol: OCEL · New CUSIP: ..."
11/02/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3 OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement effective as of October 29, 2021 by and between Organicell Regenerative Medicine, Inc., a Nevada corporation and holders of common stock of the Company who were issued shares under various consulting and employment agreements during 2021 , and the Company’ s Management and Consultants Performance Stock Plan . Each of the Service Providers and the MCP Plan Holders may be referred to as a “Holder”, and collectively, the “Holders”). A. The Service Providers were issued an aggregate of 30,300,000 shares of the Company’ s common stock during 2021 pursuant to various consulting and employment agreements . B. The MCP Plan ..."
08/31/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy